Verified Panel · Virtual · IRB-Ready
Built for small populations and high-stakes decisions
When you are developing therapies or communications for rare and ultra-rare diseases, you cannot afford to rely on generic research methods. Patient populations are small, geographically dispersed, and often living with diagnoses that carry significant emotional weight.
MedPanel’s rare disease focus groups are designed for exactly this environment — combining a verified global panel, IRB-ready protocols, and specialists who understand the particular dynamics of qualitative research in rare disease settings. Whether your objective is label comprehension, disease awareness testing, or capturing authentic patient and caregiver perspectives, MedPanel gives you the structural rigor and the human sensitivity to do it right.
1 in 2,000 to 1 in 10,000
Below 1 in 10,000 · dyad / triad
Secure, HIPAA-aligned virtual
Trauma-informed facilitation
A Virtual Platform Built for Rare Disease Realities
Finding five to eight patients with the same ultra-rare condition in a single metro area is rarely possible. MedPanel’s focus groups run entirely on a secure, HIPAA-aligned virtual platform, removing geography as a barrier without sacrificing the depth of interaction that in-person formats traditionally delivered.
Technical requirements are minimal by design. Participants need only a standard internet connection and a device with a camera — no proprietary software installation, no IT-heavy onboarding. Moderators and observers access a separate back-channel interface for real-time note-sharing and stimulus delivery, keeping the participant experience clean and uninterrupted. All sessions are recorded with participant consent, and recordings are securely archived within MedPanel’s compliant infrastructure.
For sponsors requiring a third-party IRB review, MedPanel supports full documentation handoffs — including screener instruments, discussion guides, consent language, and data handling protocols. Our team has navigated IRB submissions for rare disease studies across oncology, neurology, metabolic disorders, and immunology, so we are not learning your compliance requirements at your expense.
Group Size Is a Clinical Decision, Not a Logistical One
In standard qualitative research, focus groups of eight to ten participants are common. In rare disease research, that default is often inappropriate — and sometimes impossible to achieve. MedPanel structures group size around condition prevalence and participant burden.
- Rare disease conditions (prevalence 1 in 2,000 to 1 in 10,000). Groups of 6–8 are typically feasible and allow for meaningful cross-patient dialogue. Participants benefit from the peer recognition that comes from sharing a room — even a virtual one — with others who understand their experience firsthand.
- Ultra-rare conditions (prevalence below 1 in 10,000, or highly fragmented communities). Groups of 2–4 are standard. At this scale, MedPanel moderators shift toward an in-depth dyad or triad format, preserving exploratory depth while ensuring no participant is left without airtime. The resulting data is qualitative in nature but analytically rich when triangulated with findings from your broader qualitative research program.
Smaller groups also reduce the emotional exposure risk for participants. In rare disease settings — particularly pediatric conditions, progressive neurological diseases, or diagnoses with high mortality salience — a large group format can inhibit candor or trigger distress. MedPanel moderators are trained in trauma-informed facilitation techniques appropriate for these contexts.
Where Rare Disease Focus Groups Deliver the Most Value
Rare disease focus groups are not interchangeable with broad patient advisory panels or ad-hoc interviews. They are most valuable when you need structured group interaction to surface reactions, language, and shared meaning that individual interviews cannot replicate. MedPanel supports four primary use cases.
Label comprehension testing
FDA’s patient labeling guidance increasingly expects sponsors to demonstrate that patients and caregivers can accurately interpret prescribing information and medication guides. Focus groups allow you to observe how participants process complex dosing instructions, risk language, and indication statements in real time — and to probe the reasoning behind misinterpretations before label finalization.
Disease awareness materials review
Before rare disease awareness campaigns reach patients and advocacy communities, they need to be tested against the actual cognitive and emotional responses of the people they are meant to reach. Focus groups surface terminology that feels clinical versus accessible, imagery that resonates versus alienates, and information hierarchies that match how patients actually think about their condition.
Patient advocacy input
Rare disease patient advocacy organizations (PAOs) carry significant influence in regulatory and payer environments. Structured focus groups with advocacy-engaged patients or PAO representatives allow you to pressure-test your clinical narrative, identify patient-centered endpoints that regulators will find credible, and build genuine stakeholder alignment before you reach advisory committee submissions.
Caregiver studies
In pediatric rare diseases and conditions that impair patient communication, caregivers are not proxies — they are primary research participants in their own right. MedPanel’s caregiver studies methodology applies the same verified panel standards and IRB-ready infrastructure to caregiver groups, capturing burden, treatment decision dynamics, and information needs distinct from those of the patient.
What Makes MedPanel’s Panel Different
The quality of any focus group depends entirely on the quality of the participants. MedPanel’s panel is verified — not self-reported.
Every patient and caregiver in our network has been confirmed through a combination of physician attestation, medical record validation, and condition-specific screener protocols developed with rare disease clinical expertise.
This matters in rare disease research for a specific reason: recruitment fraud and misrepresentation are significantly higher risks when financial incentives intersect with small, hard-to-verify populations. A self-reported panel in ultra-rare disease settings can produce groups where a meaningful percentage of participants do not actually have the target diagnosis. MedPanel’s verification process eliminates that risk before recruitment begins.
Our global reach means we can assemble groups across North America, Europe, and increasingly across Asia-Pacific and Latin American markets — supporting international label comprehension studies, global awareness campaign testing, and multinational rare disease research programs anchored to your pillar research strategy.
Plan your study
Plan Your
Rare Disease Focus Group
Every rare disease program has a different recruitment timeline, regulatory context, and stakeholder landscape. MedPanel’s research team works directly with sponsors, CROs, and agency partners to scope studies that match your protocol — not a templated service package.
Feasibility confirmed for your target population
A clear recruitment timeline
A moderator with experience in your therapeutic area
Study design scoped to your protocol
Contact MedPanel to discuss your rare disease focus group study. We will confirm feasibility for your target population, outline a recruitment timeline, and connect you with a moderator who has experience in your therapeutic area.